Clinical study of metformin,dapagliflozin and semaglutide in the treatment of type 2 diabetes mellitus with poor blood glucose control
Objective To investigate the clinical value of metformin,dapagliflozin and semaglutide in the treatment of type 2 diabetes mellitus(T2DM)with poor blood glucose control.Methods A total of 92 T2DM patients with poor blood glucose control who were treated at Dongguan Kanghua Hospital from June 2021 to December 2023 were selected as the study subjects.The patients were divided into an observation group and a control group using a random number table method,with 46 cases in each group.The control group was treated with metformin combined with dapagliflozin.The observation group was treated with a combination of metformin,dapagliflozin and semaglutide.The blood glucose index,physical index,pancreatic function index,and occurrence of adverse reactions between the two groups were compared.Results After treatment,fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in the observation group were significantly lower than those in the control group,with statistically significant differences(P＜0.05).Compared with the control group,the observation group had significantly lighter body weight,significantly smaller body mass index and waist circumference after treatment,and the difference was statistically significant(P＜0.05).Compared with the control group,the observation group showed a significantly higher ncreatic β cell function index and a significantly lower homeostasis model assessment of insulin resistance after treatment,with a statistically significant difference(P＜0.05).Conclusion Metformin,dapagliflozin and semaglutide can effectively control blood glucose levels,reduce weight,and improve pancreatic function in T2DM with poor blood glucose control.
Type 2 diabetes mellitusOverweight or obeseSemaglutideMetforminDapagliflozin
万方数据
维普
